Skip to main content
. 2021 Dec 3;5(23):5047–5056. doi: 10.1182/bloodadvances.2021004908

Figure 3.

Figure 3.

NRM. The cumulative incidence of NRM for patients receiving the phase 2 dosage of pegIFNα (n = 31).